<DOC>
	<DOCNO>NCT01416246</DOCNO>
	<brief_summary>Multiple myeloma difficult treat anti-cancer medicine ( call chemotherapy ) radiation alone . Sometimes high dos chemotherapy use use also low blood count . Using cell ( special cell call stem cell ) help increase blood count high dos chemotherapy call autologous stem cell transplantation ( ASCT ) . Using stem cell restore blood count advance supportive measure ( antibiotic growth factor increase blood count ) improve safety ASCT . However , blood count still decrease period day high dos chemotherapy . During time , patient great risk infection . Studies show faster blood count recover ASCT , less risk develop unwanted side effect ASCT . Typically ASCT , patient 's stem cell give back single day . In study , investigator plan see happen small amount stem cell give back patient multiple day . The investigator want find effect good and/or bad patient multiple myeloma . Some study show give back stem cell period day help increase bone marrow activity decrease time take blood count recover ASCT . It hope new approach may lower patient 's risk side effect infection , decrease number blood transfusion patient need process , reduce time patient spend hospital , low overall treatment cost .</brief_summary>
	<brief_title>Fractionated Stem Cell Infusions Myeloma Patients Undergoing Autologous Stem Cell Transplant</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Age ≥18 &lt; = 75 Histologic serologic finding , review MSKCC , confirm diagnosis multiple myeloma . Standard diagnostic criterion multiple myeloma use , per International Myeloma Foundation consensus guideline ( Durie et al , 2003 ) . Patients must symptomatic multiple myeloma respond prior induction salvage chemotherapy ( i.e . chemosensitive disease ) : Patients receive highdose melphalan ASCT part initial therapy require least minor response last line therapy document chemosensitive disease ( Anderson et al . 2008 ) Patients receive highdose melphalan ASCT part salvage therapy require least minor response last line therapy document chemosensitive disease ( Anderson et al . 2008 ) . There limit number prior regimen receive patient . Patients must least 7 x 10^6 ( +/ 0.5 x 10^6 ) CD34+ stem cells/kg frozen he/she treat part salvage ( second ) transplant strategy ; patient must 10 x 10^6 ( +/ 0.5 x 10^6 ) CD34+ stem cells/kg frozen ASCT perform part initial therapy . Adequate organ function require , defined follow : Serum bilirubin ≤ 2.0 mg/dl AST , ALT alkaline phosphatase &lt; 3 time upper limit laboratory normal Creatinine clearance &gt; = 40 ml/min ( 24 hour urine collection calculated* ) *To calculate CockroftGault method : ( 140Age ) x Mass ( kg ) x [ 0.85 female ] ( 72 x Creatinine ( mg/dL ) LVEF &gt; = 45 % MUGA rest ECHO Diffusing capacity &gt; = 45 % ( adjust hemoglobin ) predict pulmonary function test Performance status KPS &gt; = 70 % . Unstable angina myocardial infarction within 4 month initiate therapy trial , NYHA Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , sick sinus syndrome , electrocardiographic evidence acute ischemia Grade 3 conduction system abnormalities unless subject pacemaker Pregnant lactating female Nonhematologic malignancy within past 3 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas Contraindication melphalan require supportive treatment , include hypersensitivity GCSF pegfilgrastim Any medical condition laboratory evaluation , treat physician 's principal investigator 's opinion , make patient unsuitable participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Stem cell Infusions</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>11-105</keyword>
</DOC>